JP2851288B2 - 癌診断および管理における自己分泌運動性因子 - Google Patents

癌診断および管理における自己分泌運動性因子

Info

Publication number
JP2851288B2
JP2851288B2 JP63505028A JP50502888A JP2851288B2 JP 2851288 B2 JP2851288 B2 JP 2851288B2 JP 63505028 A JP63505028 A JP 63505028A JP 50502888 A JP50502888 A JP 50502888A JP 2851288 B2 JP2851288 B2 JP 2851288B2
Authority
JP
Japan
Prior art keywords
amf
motility
cells
cancer
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP63505028A
Other languages
English (en)
Japanese (ja)
Other versions
JPH04502143A (ja
Inventor
エー． リオッタ，ランス
シッフマン，エリオット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Commerce
Original Assignee
United States Department of Commerce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of Commerce filed Critical United States Department of Commerce
Publication of JPH04502143A publication Critical patent/JPH04502143A/ja
Application granted granted Critical
Publication of JP2851288B2 publication Critical patent/JP2851288B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP63505028A 1987-06-05 1988-05-27 癌診断および管理における自己分泌運動性因子 Expired - Fee Related JP2851288B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5838187A 1987-06-05 1987-06-05
US058,381 1987-06-05

Publications (2)

Publication Number Publication Date
JPH04502143A JPH04502143A (ja) 1992-04-16
JP2851288B2 true JP2851288B2 (ja) 1999-01-27

Family

ID=22016462

Family Applications (1)

Application Number Title Priority Date Filing Date
JP63505028A Expired - Fee Related JP2851288B2 (ja) 1987-06-05 1988-05-27 癌診断および管理における自己分泌運動性因子

Country Status (6)

Country Link
EP (1) EP0362278A4 (de)
JP (1) JP2851288B2 (de)
AU (1) AU614755B2 (de)
CA (1) CA1310902C (de)
IL (1) IL86577A (de)
WO (1) WO1988009797A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019245266A1 (ko) * 2018-06-20 2019-12-26 박희성 암 유래 amf를 유효성분으로 함유하는 항암용 조성물

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE455946B (sv) * 1986-10-20 1988-08-22 Trion Forskning & Utveckling Nya pertussistoxin-polypeptider och antigener samt testsatser, vacciner och intradermala hudtestkompositioner
US5449753A (en) * 1992-01-17 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Autotaxin: motility stimulating protein useful in cancer diagnosis
US5382521A (en) * 1992-07-14 1995-01-17 Michigan Cancer Foundation Method of determining metastatic potential of bladder tumor cells
CA2238257A1 (en) * 1998-05-22 1999-11-22 Universite De Montreal Endocytosis of amf-r and uses thereof in cancer therapy
DE19847107A1 (de) * 1998-10-13 2000-04-20 Herbert Ruebben Verwendung von Pertussistoxin zur Behandlung von Tumorerkrankungen
KR100629028B1 (ko) 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
WO2001074897A2 (en) * 2000-04-03 2001-10-11 Curagen Corporation Protein amf-1 to amf-10 and nucleic acids encoding the same
EP2269638A3 (de) 2004-05-28 2012-06-13 GlaxoSmithKline Biologicals S.A. Impfstoffzusammensetzungen mit Virosomen und einem Saponin-Adjuvans
AR054020A1 (es) 2005-03-23 2007-05-30 Glaxosmithkline Biolog Sa Nuevo uso
GB0519871D0 (en) 2005-09-30 2005-11-09 Secr Defence Immunogenic agents
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
KR101515078B1 (ko) 2005-12-22 2015-04-24 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
EP2476433A1 (de) 2006-03-30 2012-07-18 GlaxoSmithKline Biologicals S.A. Immunogene Zusammensetzung
PT2422810E (pt) 2006-07-17 2014-12-03 Glaxosmithkline Biolog Sa Vacina da gripe
US9364525B2 (en) 2006-07-18 2016-06-14 Glaxosmithkline Biologicals Sa Vaccines for malaria
US8323664B2 (en) 2006-07-25 2012-12-04 The Secretary Of State For Defence Live vaccine strains of Francisella
EA015817B1 (ru) 2006-10-12 2011-12-30 Глаксосмитклайн Байолоджикалс С.А. Иммуногенная композиция, содержащая адъювант в виде эмульсии "масло в воде"
EP2433648A3 (de) 2006-10-12 2012-04-04 GlaxoSmithKline Biologicals S.A. Impfstoff mit einem Öl-in-wasser-emulsionshilfsstoff
PE20090146A1 (es) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
CA2690708A1 (en) 2007-06-26 2008-12-31 Glaxosmithkline Biologicals S.A. Vaccine
WO2009117035A1 (en) 2007-12-19 2009-09-24 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Soluble forms of hendra and nipah virus f glycoprotein and uses thereof
ES2553113T3 (es) 2008-04-16 2015-12-04 Glaxosmithkline Biologicals S.A. Vacuna
GB0900455D0 (en) 2009-01-13 2009-02-11 Secr Defence Vaccine
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
MX2012011189A (es) 2010-03-26 2013-02-07 Glaxosmithkline Biolog Sa Vacuna contra el virus e inmunodeficiencia humana.
GB201009273D0 (en) 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
EP2707025B8 (de) 2011-05-13 2017-08-23 Zoetis Services LLC Immunogene hendra- und nipah-virus-g-glycoprotein-zusammensetzungen
CN103533953A (zh) 2011-05-17 2014-01-22 葛兰素史密丝克莱恩生物有限公司 针对肺炎链球菌的疫苗
GB201120000D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
GB201119999D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
WO2014086787A1 (en) 2012-12-05 2014-06-12 Glaxosmithkline Biologicals S.A. Immunogenic composition
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
MX2016007870A (es) 2013-12-16 2016-10-07 Zoetis Services Llc Composiciones inmunogenas de glucoproteina g de los virus hendra y nipah.
BE1022949B1 (fr) 2014-06-25 2016-10-21 Glaxosmithkline Biologicals S.A. Composition immunogene
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
CN110621339A (zh) 2017-04-28 2019-12-27 葛兰素史密丝克莱恩生物有限公司 疫苗接种
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600653B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel methods
EP3581201A1 (de) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 polypeptide und verwendungen davon
CN112566654A (zh) 2018-07-31 2021-03-26 葛兰素史密丝克莱恩生物有限公司 抗原纯化方法
WO2020055503A1 (en) 2018-09-14 2020-03-19 Massachusetts Institute Of Technology Nanoparticle vaccine adjuvant and methods of use thereof
EP3886901A1 (de) 2018-11-29 2021-10-06 GlaxoSmithKline Biologicals S.A. Verfahren zur herstellung eines adjuvans
CN114126419A (zh) 2019-03-19 2022-03-01 Uab研究基金会 基于皂苷的疫苗佐剂
EP3777884A1 (de) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogene zusammensetzung
WO2021048081A1 (en) 2019-09-09 2021-03-18 Glaxosmithkline Biologicals Sa Immunotherapeutic compositions
US12533418B2 (en) 2019-11-22 2026-01-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
WO2021122551A1 (en) 2019-12-19 2021-06-24 Glaxosmithkline Biologicals Sa S. aureus antigens and compositions thereof
EP4146378A1 (de) 2020-05-05 2023-03-15 GlaxoSmithKline Biologicals S.A. Mikrofluidische mischvorrichtung und verfahren zur verwendung
WO2022029024A1 (en) 2020-08-03 2022-02-10 Glaxosmithkline Biologicals Sa Truncated fusobacterium nucleatum fusobacterium adhesin a (fada) protein and immunogenic compositios thereof
TW202214294A (zh) 2020-09-30 2022-04-16 美商碩騰服務公司 具有ｈｙａＣ及ｎａｎＰ缺失之新穎多殺性巴斯德氏菌株及疫苗
JP2023553854A (ja) 2020-12-02 2023-12-26 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ドナー鎖補完性ｆｉｍｈ
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023114570A1 (en) 2021-12-19 2023-06-22 Massachusetts Institute Of Technology Compositions and methods for long-lasting germinal center responses to a priming immunization
JP2025509460A (ja) 2022-03-14 2025-04-11 ファイザー・インク アジュバントを生産するための方法
TWI909678B (zh) 2023-09-13 2025-12-21 美商輝瑞股份有限公司 產製佐劑之方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ｐｒｏｃ．Ｎａｔｌ．Ａｃａｄ．Ｓｃｉ．，Ｕ．Ｓ．Ａ，８３（１９８６），ｐ．３３０２−３３０６

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019245266A1 (ko) * 2018-06-20 2019-12-26 박희성 암 유래 amf를 유효성분으로 함유하는 항암용 조성물

Also Published As

Publication number Publication date
IL86577A0 (en) 1988-11-15
AU614755B2 (en) 1991-09-12
CA1310902C (en) 1992-12-01
EP0362278A1 (de) 1990-04-11
EP0362278A4 (de) 1990-05-14
IL86577A (en) 1993-06-10
WO1988009797A1 (en) 1988-12-15
JPH04502143A (ja) 1992-04-16
AU1803488A (en) 1989-01-04

Similar Documents

Publication Publication Date Title
JP2851288B2 (ja) 癌診断および管理における自己分泌運動性因子
Shoji et al. Bronchial epithelial cells produce lung fibroblast chemotactic factor: fibronectin
JP3159705B2 (ja) 血管形成ペプチド
Inoue et al. Pseudomonas stimulates interleukin-8 mRNA expression selectively in airway epithelium, in gland ducts, and in recruited neutrophils.
Chiang et al. Binding of chemotactic collagen-derived peptides to fibroblasts: the relationship to fibroblast chemotaxis
JPH09291042A (ja) 医薬組成物
Clezardin et al. Thrombospondin is synthesized and secreted by human osteoblasts and osteosarcoma cells: A model to study the different effects of thrombospondin in cell adhesion
US20160046704A1 (en) Glycoproteins having lipid mobilising properties and therapeutic applications thereof
Kochi et al. Immunohistochemical study of fibronectin in human glioma and meningioma
US5219579A (en) Biologically active material characterized by catabolic activity generally associated with cachexia-inducing tumors, preparations, production and uses thereof
Beguinot et al. Functional studies on the EGF receptor with an antibody that recognizes the intracellular portion of the receptor.
JPH01110633A (ja) 肝細胞刺激因子
Miyake et al. Cell union and protein synthesis in conjugation of Blepharisma
JPH06508111A (ja) 甲状腺由来の軟骨細胞刺激因子
AU593063B2 (en) Purified human angiogenic factor, method for its preparation and pharmaceutical preparations
Arvanitis et al. Reactive astrocytes upregulate one or more gene products that are recognized by monoclonal antibody H
Koo Human α2-macroglobulin: A major serum factor cytotoxic for tumor cells
EP0417129B1 (de) Das lungenwachstum stimulierende und hemmende faktoren für krebstumorzellen
EP0681480B1 (de) Recognin vakzine
EP0646600B1 (de) Zellwachstum hemmendes Protein
JPH08506654A (ja) 前立腺疾病の検出方法および治療方法
WO1993016715A1 (en) Fsf-1 and the early detection of fibrosis
Winder et al. Immunohistochemical localisation of α-1-protease inhibitor in the horse
Varricchio et al. An albumin-like protein is the major secretory protein of ovarian epithelial cells in vivo and in vitro
JPH02157298A (ja) 新規補体制御物質

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees